As for the protein-based vaccine, in a phase 1 study, 29 patients with stage II-IV HER2-overexpressing breast and ovarian cancer were vaccinated with the intracellular domain of HER2 (amino acids 676-1255) plus GM-CSF (86). This evidence concerns the gene ERBB2 and ovarian cancer.